What’s New
Explore latest events, medical insights and trends.
LIBERTY AD CHRONOS (18+ years)
LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with
moderate-to-severe atopic dermatitis
LIBERTY AD SOLO-CONTINUE (18+ years)
LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.
LIBERTY AD HAFT (12+)
LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.
DUPIXENT delivers a high standard of efficacy in adults
Efficacy is shown through real-world evidence, skin bacterial microbiome, trans-epidermal water loss (TEWL), and nonatopic comorbidities.
Infant and young child data
Significant improvement in Worst Scratch and Itch NRS score, Skin Clearance, and Children’s Dermatology Life Quality Index (CDLQI).
DUPIXENT delivers a high standard of efficacy in children
Efficacy is shown through 3 years of disease control, impact on growth curve, and improvement in mental health.
Understanding Mucus Burden in Asthma
Review the clinical impact of mucus plugging in asthma and available evidence on changes in mucus score, mucus volume, and lung function observed in clinical studies of dupilumab.
EADV 2025 Highlight Webinar Recording Now Available
Access the full recording of the webinar to gain insights on Atopic Dermatitis, Bullous Pemphigoid, and practical applications from leading experts.
Patient-Video
Request-form
